Retatrutide Skin Side Effects: Trial Data

Retatrutide skin side effects have been reported in clinical trial data, making this an important area of information for anyone following the research into this investigational medicine. Retatrutide is an unlicensed triple incretin receptor agonist, acting on GIP, GLP-1 and glucagon receptors, with no marketing authorisation in the UK or elsewhere. It is available only to participants enrolled in an authorised clinical trial. This article summarises what the published trial data report about skin-related adverse effects, which symptoms warrant medical attention, and the risks associated with obtaining retatrutide outside a clinical trial.

What is retatrutide and what is its regulatory status in the UK?

Retatrutide holds no marketing authorisation in the UK or anywhere else and can only be accessed within an authorised clinical trial. It is an investigational triple incretin receptor agonist acting on GIP, GLP-1 and glucagon receptors.

Retatrutide holds no marketing authorisation in the UK or anywhere else, and it can be prescribed or supplied only within an authorised clinical trial.^[14] It is an investigational triple incretin receptor agonist, acting simultaneously on GIP, GLP-1 and glucagon receptors, a pharmacological profile that distinguishes it from currently licensed medicines.^[1][2] Because it is not authorised, it cannot be advertised, and no launch date or timeline for UK availability can be given.

Research into retatrutide has progressed through Phase 2 studies and into Phase 3 programmes. The TRIUMPH programme covers trials in adults with obesity, while the TRANSCEND programme covers trials in adults with type 2 diabetes.^[3] Results from these trials are being reported in peer-reviewed literature, but the evidence base is still maturing and regulatory submissions have not yet concluded.

For anyone interested in weight management now, licensed treatments exist and can be discussed with a GP. Retatrutide itself remains available only to participants enrolled in an authorised clinical trial, and no other route of access exists in the UK.

What skin side effects were reported in retatrutide clinical trials?

The 2023 Phase 2 trial reported injection-site bruising, erythema and pain, as well as alopecia in a proportion of participants. Hair loss is hypothesised to relate to rapid weight loss rather than a direct drug effect, though the mechanism is not fully established.

In the Phase 2 trial of retatrutide published in the New England Journal of Medicine (2023), injection-site reactions were among the adverse effects recorded in participants receiving the active treatment.^[1][2] These included injection-site bruising, erythema (redness) and pain at the injection site, which are consistent with class effects seen with other subcutaneously administered incretin-based therapies.

Beyond localised injection-site findings, the trial data also noted alopecia (hair loss) in a proportion of participants. This finding has been observed with other GLP-1 receptor agonist treatments and is thought to relate to rapid weight loss rather than a direct drug effect on hair follicles, though this remains a hypothesis and the precise mechanism is not fully established.^[4][5] Phase 3 data from the TRIUMPH and TRANSCEND programmes are continuing to be reported and will provide further information on the frequency and clinical significance of skin-related adverse events.

It is important to note that trial populations are carefully selected and monitored, and adverse event rates in real-world use, if the medicine were ever authorised, could differ. All figures reported here reflect findings within the controlled trial setting and should not be interpreted as predictions of individual experience.

Are certain people more likely to experience skin reactions?

People experiencing rapid weight loss appear more likely to develop alopecia, and those with a history of skin conditions may be more sensitive to injection-site reactions. Repeated injection into the same site without rotation increases the risk of localised skin changes such as lipohypertrophy.

People who experience rapid weight loss during treatment with incretin-based therapies, including participants in retatrutide trials, appear more likely to develop alopecia, as the physiological stress of significant caloric deficit can disrupt the normal hair growth cycle.^[4][5] This is not unique to retatrutide and has been reported with other agents in the same class.

Individuals with a personal or family history of skin conditions such as eczema, psoriasis or contact dermatitis may be more sensitive to injection-site reactions in general. This is a general caution applicable to subcutaneous injectables rather than a formally characterised risk factor specific to retatrutide, and the trial data do not currently identify it as such.

People who inject into the same anatomical site repeatedly without rotating the injection location are at greater risk of localised skin changes such as lipohypertrophy. Rotating injection sites is standard practice for all subcutaneous injectable medicines and is recommended in UK injection technique guidance.^[8]

Participants in retatrutide trials who are pregnant or breastfeeding are excluded from enrolment, and contraception requirements apply to those of childbearing potential, so the skin-related safety profile in pregnancy is not established. Anyone of childbearing potential participating in a clinical trial involving an investigational medicine of this class should follow the contraception guidance specified in the trial protocol.

Because the evidence base is still developing, it is not yet possible to define with precision which subgroups carry the highest risk of skin adverse effects. Participants in the TRIUMPH and TRANSCEND trials who experience skin reactions are encouraged to report them to the trial team under the study protocol.

Which skin symptoms should prompt you to seek medical advice?

Widespread rash, urticaria, facial swelling or breathing difficulty may indicate anaphylaxis and require an immediate 999 call. Persistent, worsening or spreading skin symptoms, or those accompanied by fever or joint pain, warrant prompt medical review.

Any participant in a retatrutide clinical trial who develops a widespread rash, urticaria (hives), facial swelling or difficulty breathing should treat this as a potential hypersensitivity reaction and call 999 immediately, as these features may indicate anaphylaxis. When speaking to emergency services or attending an emergency department, participants should tell clinical staff that they are enrolled in a clinical trial and, if possible, show their participant identification card. Further doses should not be taken until a clinician has reviewed the reaction. The trial team should also be contacted as soon as it is safe to do so, as the study protocol governs how adverse events are reported and managed.

Localised injection-site redness or mild bruising that resolves within a few days is generally expected and should be reported to the trial team at the next scheduled contact.

Skin symptoms that persist, worsen or spread beyond the injection site, or that are accompanied by systemic features such as fever, joint pain or fatigue, warrant prompt medical review. For those not in a trial who develop unexplained skin changes after using any injectable medicine, contacting a GP is the appropriate step, or NHS 111 for urgent advice outside normal hours.

Hair loss that is noticeable or distressing should also be discussed with a healthcare professional, both to confirm the likely cause and to rule out other contributing factors such as nutritional deficiencies.

Suspected side effects from medicines used within clinical trials should be reported to the trial team or study sponsor under the trial protocol. The MHRA Yellow Card scheme at yellowcard.mhra.gov.uk is available for reporting suspected side effects from medicines taken outside a clinical trial.

No skin symptom should be dismissed without assessment if it is causing concern, and trial participants always have the right to raise safety questions with the trial investigators.

What are the risks of obtaining retatrutide outside a clinical trial?

Any product sold online as retatrutide is not a licensed medicine and may be falsified, contaminated or mislabelled, carrying risks of severe skin infection, abscess and systemic harm. The only legitimate route to retatrutide in the UK is participation in an authorised clinical trial.

Retatrutide cannot be legally purchased, prescribed or supplied outside an authorised clinical trial in the UK, and any product sold online or through informal channels under this name is not a licensed medicine and may be falsified, contaminated or mislabelled. The risks of injecting an unverified substance are serious and include severe local skin reactions, systemic infection, abscess formation and unpredictable systemic effects from unknown ingredients.

Falsified injectable products have been associated with significant harm in published case reports, including necrotising skin infections and bloodborne pathogen transmission. The MHRA has issued safety alerts about falsified versions of licensed GLP-1 receptor agonist products, such as counterfeit Ozempic, circulating in the UK supply chain.^[10][11] Because retatrutide has no authorised formulation available outside trials, there is no legitimate reference standard against which an online product could be verified, making the risk of harm from counterfeit material particularly high.

Anyone who has injected a product purchased outside a clinical trial and develops skin redness, swelling, pain, discharge or systemic symptoms should seek medical attention promptly by contacting their GP or, if symptoms are severe or rapidly worsening, attending an emergency department.

The safest and only legitimate route to retatrutide in the UK is participation in an authorised clinical trial. Information about ongoing trials can be found through the NIHR Be Part of Research portal at bepartofresearch.nihr.ac.uk or the EU Clinical Trials Register. Licensed weight-management treatments are available through NHS and regulated private routes and can be discussed with a GP.

Scientific References

1. Triple–Hormone-Receptor Agonist Retatrutide for Obesity.
2. Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
3. Retatrutide for the treatment of obesity, obstructive sleep apnoea and related conditions: the TRIUMPH clinical development program.
4. GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms.
5. Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes.
6. The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms.
7. Integrating glucagon-like peptide-1 receptor agonists into dermatology practice: Safety and monitoring strategies.
8. New injection recommendations for patients with diabetes.
9. Anaphylaxis.
10. MHRA warns of unsafe fake weight loss pens.
11. Ozempic (semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products.
12. EMA alerts EU patients and healthcare professionals to reports of falsified Ozempic pens.
13. Clinical trials – Be Part of Research.
14. Medicines and Healthcare products Regulatory Agency.
15. Necrotising fasciitis.

Frequently Asked Questions